GUILLERMO GARCIA-MANERO to Clinical Trials, Phase I as Topic
This is a "connection" page, showing publications GUILLERMO GARCIA-MANERO has written about Clinical Trials, Phase I as Topic.
Connection Strength
0.150
-
Can we improve outcomes in patients with acute myelogenous leukemia? Incorporating HDAC inhibitors into front-line therapy. Best Pract Res Clin Haematol. 2012 Dec; 25(4):427-35.
Score: 0.088
-
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 2008 Feb 01; 111(3):1060-6.
Score: 0.062